ホーム » 研究業績/Publication » Publication 2016
- Recent
- 2017
- 2016
- 2015
- 2014
- 2013
- 2012
- 2011
- 2010
- 2009
- 2008
- 2007
- 2006
- 2005
- 2004
- 2003
- 2002
- 2001
- 2000
- 1999
- 1998
Publication 2016
Ishida Y., Yoneda M., Otsuki H., Watanabe Y., Kato F., Matsuura K., Kikukawa M., Matsushita S., Hishiki T., Igarashi T., Miura T. Generation of a neutralization-resistant CCR5 tropic SHIV-MK38 molecular clone, a derivative of SHIV-89.6. Journal of General Virology. in press, 2016
Ohashi N., Harada S., Mizuguchi T., Irahara Y., Yamada Y., Kotani M., Nomura W., Matsushita S., Yoshimura K., Tamamura H. Small molecular CD4 mimics containing mono-cyclohexyl moieties as HIV entry inhibitors. ChemMedChem, in press, 2016.
Maruta Y., Kuwata T., Tanaka K., Alam M., Ramirez-Valdez K-P., Egami Y., Yoshiaki Suwa Y., Morioka H., Matsushita S. Cross-neutralization activity of single-chain variable fragment (scFv) derived from anti-V3 monoclonal antibodies mediated by post-attachment binding. Jpn. J. Infect. Dis.,in press, 2016
Mizuguchi T., Harada S., Miura T., Ohashi N., Narumi T, Mori H.; Irahara Y; Yamada Y.; Nomura W., Matsushita S., Yoshimura K, Tamamura H. Minimally cytotoxic CD4 mimic as an HIV entry inhibitor. Bioorg Med Chem Lett. 26:397-400, 2016.
Boonchawalit, S., Harada, S, Shirai, N., Gatanaga, H., Oka, S., Matsushita, S., and Yoshimura, K. Impact of maraviroc-resistant mutation M434I in the C4 region of HIV-1 gp120 on sensitivity to antibody-mediated neutralization. Jpn. J. Infec.t Dis., in press, 2016.
Kuwata, T., Enomoto, I., Baba, M. and Matsushita S. Incompatible natures of HIV-1 envelope in resistance to the CCR5 antagonist cenicriviroc and neutralizing antibodies．Antimicrobial Agents and Chemotherapy (AAC), 60(1), 437-450, 2016. doi: 10.1128/AAC.02285-15